1. INTRODUCTION {#sec1}
===============

Cytokeratins are type I and II intermediate filament proteins, and cytokeratin 19 fragments (CYFRA 21-1) have been used as tumor markers for Non-Small Cell Lung Cancer (NSCLC). Vimentin is the type III intermediate filament protein that is widely expressed in mesenchymal cells. Vimentin is also expressed in a variety of cancer cells such as prostate, ovarian and lung cancers, and particularly in poorly differentiated, metastatic, or invasive cancers \[[@r1]-[@r5]\]. In studies of lung cancer, vimentin was detected in 145 of 295 NSCLC cases (49.2%) by immunohistochemistry \[[@r6]\]. Vimentin expression was associated with the histology (other types than adenocarcinoma and squamous cell carcinoma) and the poor differentiation status of NSCLCs, and with the occurrence of metastasis \[[@r6]\]. Vimentin expression was also shown to be associated with a poor prognosis in NSCLC patients who underwent surgery \[[@r5], [@r7]\]. It is also known that vimentin is a marker of epithelial to mesenchymal transition (EMT) \[[@r8]\]. Generally, cancer cells that have undergone an EMT show a high grade of malignancy and have invasive or metastatic potential \[[@r9]\]. These findings suggested that the expression of vimentin in tissue samples could be positively associated with a high grade of malignancies, including lung cancer. However, the significance of vimentin expression on the prognosis of patients with advanced lung cancer has never been studied.

When tested in the serum samples of patients with hepatocellular carcinoma, the vimentin level was significantly higher in small tumors (\<2 cm) than in non-neoplastic controls (*p\<*0.01), and was found to be more useful rather than serum alpha-fetoprotein \[[@r10]\]. Serum vimentin might be useful as a tumor marker in patients with lung cancer. However, the significance of the serum vimentin level in lung cancer patients has never been reported.

In the present study, we assessed the association of vimentin expression with survival in advanced lung cancer patients. In addition, we measured the vimentin concentrations in sera and pleural effusions in lung cancer patients and compared with known tumor markers such as CYFRA 21-1, to determine the significance of the serum vimentin level in lung cancer.

2. PATIENTS AND METHODS {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

This study was approved by the Institutional Review Board of Kagawa University (H25-053). Patients with pathologically confirmed advanced (stage III or IV) lung cancer who presented to the Department of Internal Medicine, Kagawa University Hospital between November 2013 to March 2018 and provided written informed consent were included. The lung cancers were staged according to the 7^th^ edition of the TNM classification \[[@r11]\]. Patients who had undergone surgical treatment for lung cancer and those who had another concomitant active malignancy were excluded. For comparison, non-lung cancer patients who provided written informed consent for their materials to be used were also included. Relevant clinical and laboratory data were collected from the patients\' medical records. Patient's daily living activities were expressed by Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (available at <https://ecog-acrin.org/resources.ecog-performance-status>).

2.2. Measurement of Serum Vimentin, CEA, and CYFRA21-1 Concentrations {#sec2.2}
---------------------------------------------------------------------

The concentration of serum vimentin was measured by a human vimentin Enzyme-Linked Immunosorbent Assay (ELISA) kit (\#CSB-E08982h, Cusabio Biotech, College Park, MD, USA or \#MBS721933, MyBioSource, San Diego, CA) according to the manufacturer's instructions. The serum was diluted at 1:100 (\#CSB-E08982h) or not diluted (\#MBS721933) for the ELISA to prepare the appropriate measurable range of vimentin concentrations. Serum carcinoembryonic antigen (CEA) was measured by a chemiluminescence immunoassay kit (Architect 47-0522/R04; Abbott Japan Co., Tokyo, Japan). Serum CYFRA21-1 was measured by an electro-chemiluminescence immunoassay kit (ECLusys reagent CYFRA; Roche Diagnostics, Ritkreuz, Switzerland).

2.3. Vimentin Immunostaining {#sec2.3}
----------------------------

The immunostaining and the assessment of vimentin in tissue and cell block samples were performed as described \[[@r5]\]. Briefly, samples were fixed with 10% phosphate-buffered formalin, and paraffin-embedded sections were immunohistochemically examined using anti-vimentin antibody (Clone V9, \#M0725; Dako, Glostrup, Denmark) using a Ventana BenchMark XT autostainer (Ventana Medical Systems, Tucson, AZ). All areas of each tumor were evaluated, and the percentage of tumor cells that expressed vimentin at any intensity level was calculated. A positive case was defined as the presence of \>5% of cancer cells that express vimentin.

2.4. Detection of *EGFR* Mutations and *ALK* Fusions {#sec2.4}
----------------------------------------------------

Epidermal Growth Factor Receptor (EGFR) mutations were examined by the Cobas EGFR Mutation Test (Roche Diagnostics). Anaplastic Lymphoma Kinase (ALK) fusions were examined by immunohistochemistry (Nichirei's N-Histofine ALK detection kit; Nichirei Biosciences inc., Tokyo, Japan) and fluorescence in situ hybridization (Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe; Abbott).

2.5. Statistical Analysis {#sec2.5}
-------------------------

Student's *t*-test was used to compare two-group data (vimentin concentrations). The data are expressed as means ± standard error of the mean. Overall Survival (OS) was defined as the time between the date of diagnosis and the date of death from any cause. OS curves were constructed by the Kaplan-Meier method, and the differences in OS were assessed using the log-rank test. All statistical analyses were conducted using Excel 2013 and Ekuseru-Toukei 2015 software (Social Survey Research Information, Tokyo).

3. RESULTS {#sec3}
==========

3.1. Patients and Clinical Samples {#sec3.1}
----------------------------------

One hundred and four lung cancer patients and 19 non-lung cancer patients were included in this study. The characteristics of lung cancer patients are shown in Table **[1](#T1){ref-type="table"}**. We obtained 157 clinical samples from 113 patients (94 with lung cancer and 19 with non-lung cancer) before the administration of treatment (chemotherapy and/or radiotherapy) for lung cancer. These samples include 113 peripheral blood samples and 44 pleural effusion samples. Tissue and cell block samples were prepared from liquid cell samples such as pleural effusions and the wash from a bronchoscopic examination.

3.2. Overall Survival of Lung Cancer Patients {#sec3.2}
---------------------------------------------

The Kaplan-Meier survival curves illustrate that the patients with poor ECOG PS showed shorter overall survival (Fig. (**[1A](#F1){ref-type="fig"}**), median 115 *vs* 486 days, *p*\<0.0001). Patients with driver gene mutations, that is, *EGFR* mutations or *ALK* fusions, had longer survival (Fig. (**[1B](#F1){ref-type="fig"}**), median 507 *vs* 317 days, *p*=0.0140). An elevated serum CYFRA21-1 concentration was associated with poor survival (Fig. (**[1C](#F1){ref-type="fig"}**), median 258 vs 614 days, *p*=0.0195). Serum Carcinoembryonic Antigen (CEA) concentration were not related to survival (Fig. (**[1D](#F1){ref-type="fig"}**).

3.3. Vimentin Expression in Tissue and Cell Block Samples {#sec3.3}
---------------------------------------------------------

To confirm that some lung cancer cells express vimentin, we assessed the vimentin expression by immunostaining in 36 tissue samples and 15 cell block samples. Both tissue and cell block samples were available in 7 patients. Thus vimentin expressions in tumor samples were assessed in 43 patients. Twenty-one tumors were positive and 22 were negative for vimentin (a representative of positivity in cell block samples is shown in Figs. (**[2A](#F2){ref-type="fig"}**) and (**[2B](#F2){ref-type="fig"}**), demonstrating that vimentin is certainly expressed in some lung cancer cells. All 43 NSCLC patients underwent chemotherapy and/or molecular targeted therapy. No significant difference was found in the Kaplan-Meier survival curves for OS (Fig. (**[2C](#F2){ref-type="fig"}**), median 507 vs. 392 days, *p*=0.2654) in patients with positive *versus* negative for vimentin. When analyzed in patients limited in stage IV, no difference in OS was still observed between vimentin positivity.

3.4. The Serum Vimentin Concentrations {#sec3.4}
--------------------------------------

When used an ELISA kit (CSB-E08982h), no significant difference was revealed in the serum vimentin concentration between the patients with lung cancer (n=69) and those with non-lung cancer (n=15, including five infectious disease and three bronchial asthma patients) (Fig. **[3A](#F3){ref-type="fig"}**) or between the patients with NSCLC (n=57) and those with small-cell lung cancer (SCLC) (n=12) (Fig. **[3B](#F3){ref-type="fig"}**), although the standard curves were drawn without any problem (data not shown). We also measured the vimentin concentration in pleural effusions (n=22). No significant difference in the concentration was observed whether cancer cells were detected (malignant pleural effusion) or not in pleural effusions (Fig. **[3C](#F3){ref-type="fig"}**). In addition, there was no significant difference in the vimentin concentration between the serum and the malignant pleural effusion in six patients for whom both samples were available (data not shown).

To determine whether the non-positivity of serum vimentin in lung cancer patients is true, we additionally measured the concentrations of vimentin using another ELISA kit (\#MBS 721933). Clear standard curves were acquired with this ELISA kit (data not shown). However, there was no significant difference in the concentration of serum vimentin between the patients with lung cancer (n=25) and those with non-lung cancer (n=4, including chronic obstructive pulmonary diseases and interstitial lung diseases) (Fig. **[3D](#F3){ref-type="fig"}**), or between the patients with NSCLC (n=20) and those with SCLC (n=5) (Fig. **[3E](#F3){ref-type="fig"}**).

In addition, no significant difference in vimentin concentrations was observed in the pleural effusions between the malignant pleural effusions (n=13) and the non-malignant pleural effusions (n=9) (Fig. **[3F](#F3){ref-type="fig"}**).

4. DISCUSSION {#sec4}
=============

Our findings demonstrated that (**1**) the vimentin expression was not associated with survival in advanced lung cancer patients, (**2**) elevated serum CYFRA 21-1 concentration was associated with poor survival, (3) the vimentin concentration was not increased in the sera or malignant pleural effusions of patients with advanced lung cancer. The absence of a significant difference in vimentin concentrations between lung cancer and non-lung cancer was confirmed by two commercially available ELISA kits. These findings suggest that the serum vimentin concentration is not useful as a tumor marker of lung cancer.

Previous studies using mesenchymal cells cultured *in vitro* have indicated that vimentin is largely insoluble \[[@r12], [@r13]\]. Vimentin solubility was reported to be associated with substrate stiffness as well as aspects of the cellular environment such as serum starvation, cell-cell contacts, and other cytoskeletal assemblies including myosin and actin \[[@r13]\]. Although the expression of vimentin as well as, those of cytokeratin and actin would be dynamically dependent on the *in vivo* cellular environment, the vimentin release into sera seems to be too faint for use as a tumor marker of lung cancer.

In NSCLC patients who underwent surgery, the vimentin expression assessed by immunostaining was associated with a poor prognosis \[[@r5], [@r7]\]. In the present study, however, there was no significant difference in OS between the vimentin-positive and negative patients. Judged from small sample size (n=43), vimentin expression might not predict the prognosis of patients with advanced lung cancer.

The current study demonstrated that elevated serum CYFRA 21-1 concentration was associated with poor survival. Several studies have reported an association of CYFRA 21-1 with prognosis in NSCLC patients \[[@r14]-[@r21]\]. An elevated serum CYFRA 21-1 concentration showed shorter survival in patients treated with pemetrexed-based chemotherapy or EG FR-TKIs \[[@r15]-[@r18]\]. Another study reported that NSCLC patients with high serum CEA and normal serum CYFRA 21-1 concentrations had a longer survival \[[@r19]\]. Basically, cytokeratins negatively regulate the invasive potentials of several kinds of cancer cells including lung cancer \[[@r22]-[@r24]\]. Nevertheless, an elevated CYFRA 21-1 is commonly associated with poor prognosis. Such a negative correlation of CYFRA 21-1 and prognosis could reflect tumor burden \[[@r24]\]. In fact, a high CYFRA 21-1 concentration was correlated with the advanced stage as well as shorter OS \[[@r20]\]. Interestingly, it was recently reported that a higher serum CYFRA 21-1 concentration (more than 2.2 ng/mL) is a predictor of a favorable outcome in patients treated with nivolumab \[[@r21]\]. In the era of combination of chemotherapy and immune checkpoint inhibitors, the significance of serum CYFRA 21-1 as a predictor of prognosis would change.

CONCLUSION
==========

The serum vimentin concentration is not as useful as a tumor marker of lung cancer. Vimentin expression in tumor samples might not predict patients' prognosis in patients with advanced lung cancer. An elevated serum CYFRA 21-1 concentration is associated with poor overall survival in advanced lung cancer patients.
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![Kaplan-Meier curves of overall survival in patients with advanced lung cancer, dependent on the status of (**A**) ECOG performance status, (**B**) Presence or absence of *EGFR* mutations or *ALK* fusions, (**C**) Serum CYFRA21-1, and (**D**) Serum CEA.](TORMJ-13-31_F1){#F1}

![(**A and B**) A representative of vimentin positivity in lung cancer cells. (**A**) Hematoxylin-eosin staining and (**B**) Immunostaining of vimentin in a cell block sample obtained from a patient with adenocarcinoma. (**C**) Kaplan-Meier curves of overall survival in patients with advanced lung cancer, dependent on the status of vimentin positivity based on immunostaining.](TORMJ-13-31_F2){#F2}

![The vimentin concentrations in clinical samples measured by ELISA kits: (**A-C**) CSB-E08982h (Cusabio Biotech) and (*D-F*) MBS721933, (MyBioSource). (*A*) Serum vimentin in patients with lung cancer *vs*. non-lung cancer. (*B*) Serum vimentin in patients with NSCLC *vs*. SCLC. (*C*) Vimentin in pleural effusions in which cancer cells are present *vs*. absent. (*D*) Serum vimentin in patients with lung cancer *vs*. non-lung cancer. (*E*): Serum vimentin in patients with NSCLC *vs*. SCLC. (*F*): Vimentin in pleural effusions in which cancer cells are present *vs*. absent.](TORMJ-13-31_F3){#F3}
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